Matter of Mind (UK)
The UK's most politically active psychedelic medicine advocacy organization — driving the parliamentary case for psilocybin rescheduling from Schedule 1 to Schedule 2.
Type: Advocacy
Location: London, UK
Membership: Open coalition; patient and researcher membership
Venues: UK Parliament; London conference venues; online
Activities: Parliamentary advocacy for psilocybin rescheduling in the UK, patient story amplification, media work, coalition building with clinical researchers at Imperial College and King's College London.
About
Matter of Mind is a UK-based psychedelic medicine advocacy organization focused on changing UK law to reclassify psilocybin from Schedule 1 (no recognized medicinal value, no research without exceptional licensing) to Schedule 2 (controlled medicine, researchable and prescribable). The organization brings together patient voices, clinical researchers, and policy advocates to make the parliamentary case for reform.
The current UK Schedule 1 status of psilocybin creates extraordinary bureaucratic barriers for clinical researchers, requiring Home Office licenses that are expensive, slow to process, and have limited researcher awareness. This regulatory burden has kept the UK's clinical trial capacity well below what the scientific interest in psilocybin warrants, despite the world-leading research being conducted at Imperial College London and King's College London.
Matter of Mind works directly with Members of Parliament, provides expert testimony for parliamentary inquiries, and coordinates media campaigns featuring patient stories of psilocybin therapy received abroad or in clinical trials — making the case that UK patients are being harmed by an outdated scheduling decision.
Why It Matters
The UK's Schedule 1 classification of psilocybin is the primary barrier to expanding the British clinical research program that has already produced world-leading neuroscience. Rescheduling would unlock research capacity and, eventually, prescription access — making Matter of Mind's parliamentary work one of the most consequential advocacy efforts in global psychedelic medicine.
